ArticleFrontiers in artificial intelligence2026
PredictRx: AI based decision support tool for molecular screening for breast cancer drug recommendation.
Article in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer remains one of the leading causes of cancer-related mortality rate worldwide, and the identification of effective drug combinations is an essential requirement in pharmaceutical research. The integration of Artificial Intelligence (AI) in processing large volumes of chemical and biological data combines molecular representation, predictive modeling and structured support within a single accessible tool, which accelerates early-stage candidate identification for breast cancer research while promoting reproducibility, transparency and user centered design. Aim: The current research focuses on developing and designing "PredictRx" which is an artificial intelligence based driven decision support tool which tends to benefit healthcare practioners to analyze the combination of drug which can be utilized for breast cancer patients. Methodology: PredictRx was developed using molecular descriptors, physicochemical properties, and drug interaction datasets collected from publicly available biomedical databases. The tool integrates in total six supervised and unsupervised learning techniques to examine the structural similarities between compounds and predict the potential drug interactions for breast cancer. Various machine learning techniques, including Random Forest, Support Vector Machine, Logistic Regression, K-Means Clustering, DBSCAN, and Agglomerative Clustering, to analyse structural similarities and predict potential drug interactions and synergy patterns. Model performance was evaluated using Classification matrix, Silhouette Score, Calinski-Harabasz Index, and Davies-Bouldin Index. The tool was deployed as a browser-accessible web application for real-time interaction and visualization. Result: The results suggests that Random Forest has the highest predictive performance accuracy of 1, and Agglomerative clustering delivered strongest scores (Silhouette Score: 0.6946; Davies-Bouldin Index: 0.2457). The current tool was deployed as a browser accessible web tool with possibility of real time interaction and result visualization. PredictRx is a distinctive easy to use, and interpretable screening tool focused on drug compatibility and synergy analysis. EDA further identified molecular weight, lipophilicity, and structural similarity as important contributors to drug compatibility prediction. Conclusion: PredictRx shows how AI-driven predictive modeling which can speed up molecular screening and early-stage breast cancer medication discovery. The technology facilitates the effective identification of appropriate drug combinations and offers a scalable foundation for upcoming AI-assisted pharmaceutical research by combining clustering, classification, molecular representation, and visualization into a single interpretable platform.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.